Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Phase 1/Phase 2
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT)
in combination with docetaxel and prednisone for the first-line treatment of metastatic
hormone-refractory prostate cancer (mHRPC).
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
The purpose of this study is to compare progression free survival for SU011248 [sutent
(sunitinib malate)] versus standard of care therapy in patients with previously treated,
advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib
alone in patients with advanced/metastatic lung cancer who have received previous treatment
with a platinum-based regimen
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.